MAB1794
Anti-Human B cells (CD19) Antibody, clone FMC63
clone FMC63, Chemicon®, from mouse
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
B-lymphocyte Surface Antigen B4
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.43
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
FMC63, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
flow cytometry: suitable
immunofluorescence: suitable
isotype
IgG2a
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... CD19(930)
Related Categories
General description
BIOCHEMISTRY:
p I = 7.0
p I = 7.0
Specificity
This specificity of this antibody is equivalent to that of CD19 monoclonal antibodies (Zola et al., 1988, 1989), based on comparative studies, antigen recognition and positive reaction with a CD19 transfected cell line. It detects a 96 kD single chain glycoprotein on the surface of human B lineage cells, including pre-B cells. B cells can be detected in peripheral blood and tissues. The antibody reacts with most B cell malignancies including chronic lymphocytic leukemia and most lymphomas, but not multiple myeloma.
Cell reactivity:
Normal:Stains all B lymphocytes in peripheral blood and spleen. Negative on granulocytes, monocytes, platelets, erythrocytes and T lymphocytes.
Clinical:
B cell chronic lymphocytic leukemia (B-CLL) +
Pro lymphocytic leukemia (PLL) +
Hairy cell leukemia (HCL) +
Common acute lymphoblastic leukemia (CALL) +
Pre-B acute lymphoblastic leukemia (pre-B-ALL) +
NULL-acute lymphoblastic leukemia (NULL-ALL) +
T common lymphocytic leukemia (T-CLL) -
Cell reactivity:
Normal:Stains all B lymphocytes in peripheral blood and spleen. Negative on granulocytes, monocytes, platelets, erythrocytes and T lymphocytes.
Clinical:
B cell chronic lymphocytic leukemia (B-CLL) +
Pro lymphocytic leukemia (PLL) +
Hairy cell leukemia (HCL) +
Common acute lymphoblastic leukemia (CALL) +
Pre-B acute lymphoblastic leukemia (pre-B-ALL) +
NULL-acute lymphoblastic leukemia (NULL-ALL) +
T common lymphocytic leukemia (T-CLL) -
Immunogen
Raji cells
Application
Research Category
Inflammation & Immunology
Inflammation & Immunology
Research Sub Category
Immunoglobulins & Immunology
Immunoglobulins & Immunology
This Anti-Human B cells CD19 Antibody, clone FMC63 is validated for use in FC, IF for the detection of CD19.
This antibody is useful for enumerating normal B lymphocytes and typing B cell malignancies by flow cytometry and immunofluorescence.
SUGGESTED USAGE DILUTION
Flow cytometry and Indirect Immunofluorescence 1:25
Dilute with isotonic buffer. Use 50 μl of diluted antibody per 1 x 10E6 peripheral blood mononuclear cells (PBMC) in 100 μl buffer.
SUGGESTED USAGE DILUTION
Flow cytometry and Indirect Immunofluorescence 1:25
Dilute with isotonic buffer. Use 50 μl of diluted antibody per 1 x 10E6 peripheral blood mononuclear cells (PBMC) in 100 μl buffer.
Linkage
Replaces: CBL141
Physical form
Format: Purified
Purified from mouse ascitic fluid. The antibody is supplied in 25 mM Tris-HCl buffer, 0.4 M NaCl, pH 8.0, containing 0.2% bovine serum albumin and 0.1% sodium azide. The characteristics of each lot are tested by electrophoresis and flow cytometry.
Storage and Stability
Store at 2 to 8°C, for up to 6 months. For prolonged periods, store below -20°C in undiluted aliquots. AVOID REPEATED FREEZE/THAW CYCLES.
WARNING: The monoclonal reagent solution contains 0.1% sodium azide as a preservative. Due to potential hazards arising from the build up of this material in pipes, spent reagent should be disposed of with liberal volumes of water.
WARNING: The monoclonal reagent solution contains 0.1% sodium azide as a preservative. Due to potential hazards arising from the build up of this material in pipes, spent reagent should be disposed of with liberal volumes of water.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ye Lin et al.
Frontiers in neurology, 13, 808322-808322 (2022-03-18)
Myasthenia gravis (MG) is an autoimmune disease mediated by B cells secreting autoantibodies. Regulatory B (Breg) cells confirmed to have an immunosuppressive function play an important role in many autoimmune diseases. However, what about the changes in Breg cells in
Fabiana Zappala et al.
Science advances, 8(18), eabn4613-eabn4613 (2022-05-07)
Extensive antibody engineering and cloning is typically required to generate new bispecific antibodies. Made-to-order genes, advanced expression systems, and high-efficiency cloning can simplify and accelerate this process, but it still can take months before a functional product is realized. We
Stephanie N Shishido et al.
Journal for immunotherapy of cancer, 12(2) (2024-02-14)
Chimeric antigen receptor (CAR)-T cells are approved for use in the treatment of hematological malignancies. Axicabtagene ciloleucel (YESCARTA) and brexucabtagene autoleucel (TECARTUS) genetically modified autologous T cells expressing an anti-CD19 scFv based on the FMC63 clone have shown impressive response
Christine Ambrose et al.
PloS one, 16(3), e0247701-e0247701 (2021-03-19)
Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely. Here we address this constellation of critical attributes for successful cellular therapy
Xing Du et al.
Cancer research, 68(15), 6300-6305 (2008-08-05)
B-cell malignancies routinely express surface antigens CD19 and CD22. Immunotoxins against both antigens have been evaluated, and the immunotoxins targeting CD22 are more active. To understand this disparity in cytotoxicity and guide the screening of therapeutic targets, we compared two
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service